Preclinical development of antiviral drugs

Clinical Infectious Diseases

Volumn 22, Issue 2, 1996, Pages 355-360

  Szczech, George M ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b Triangle Pharmaceutical Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS INFECTION;

EID: 0030022182     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.2.355     Document Type: Review

References (25)

1. Dornsife RE, St Clair MH, Huang AT, et al. Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother 1991;35:322-8.
2. Dornsife RE, Averett DR. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in HIV-positive humans. Antimicrob Agents Chemother (in press).
3. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activites, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992;36:2686-92.
4. Chamberlain SD, Biron KK, Dornsife RE, Averett DR, Beauchamp L, Koszalka GW. An enantiospecific synthesis of the human cytomegalovirus antiviral agent [(R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-methoxy)-4-hydroxybutyl] phosphonic acid. J Med Chem 1994; 37:1371-7.
5. Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992;327:782-9.
6. Beauchamp LM, Krenitsky TA. Acyclovir prodrugs: the road to valaciclovir. Drugs of the Future 1993;18:619-28.
7. Beauchamp LM, Orr GF, de Miranda P, Burnette T, Krenitsky TA. Amino acid ester prodrugs of acyclovir. Antiviral Chemistry and Chemotherapy 1992;3:157-64.
8. Szczech GM, Tucker WE Jr. Nail loss and footpad erosions in Beagle dogs given BW134U, a nucleoside analog. Toxicol Pathol 1985;13:181-4.
9. Tucker WE Jr, Krasny HC, de Miranda P, et al. Preclinical toxicology studies with acyclovir: carcinogenicity bioassays and chronic toxicity tests. Fundam Appl Toxicol 1983;3:579-86.
10. Szczech GM, Tucker WE Jr. Dose selection as it pertains to testing a prodrug in carcinogenicity bioassays. Toxicol Pathol 1983;11:55-9.
11. Burnett TC, de Miranda P. Purification and characterization of an enzyme from rat liver that hydrolyzes 256U87, the L-valyl ester prodrug of acyclovir (ZOVIRAX®). Antiviral Research 1993;20(suppl 1):115.
12. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
13. Nusinoff-Lehrman S, Smiley L, Szczech G, et al. Update on acyclovir prodrugs. In: Mills J, Corey L, eds. Antiviral chemotherapy; new directions for clinical application and research. New York: Prentice Hall, 1993;3:97-104.
14. Tucker WE Jr, Macklin AW, Szot RJ, et al. Preclinical toxicology studies with acyclovir: acute and subchronic tests. Fundam Appl Toxicol 1983;3:573-8.
15. Moore HL Jr, Szczech GM, Rodwell DE, Kapp RW Jr, de Miranda P, Tucker WE Jr. Preclinical toxicology studies with acyclovir: teratologic, reproductive and neonatal tests. Fundam Appl Toxicol 1983; 3:560-8.
16. Clive D, Turner NT, Hozier J, Batson AG, Tucker WE Jr. Preclinical toxicology studies with acyclovir: genetic toxicity tests. Fundam Appl Toxicol 1983;3:587-602.
17. Averett DR, Koszalka GW, Fyfe JA, Roberts GB, Purifoy DJM, Krenitsky TA. 6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob Agents Chemother 1991;35:851-7.
18. Koszalka GW, Averett DR, Fyfe JA, et al. 6-N-Substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus. Antimicrob Agents Chemother 1991;35:1437-43.
19. Jones LA, Moorman AR, Chamberlain SD, et al. Di- and triester prodrugs of the varicella-zoster antiviral agent 6-methoxypurine arabinoside. J Medicinal Chem 1992;35:56-63.
20. Chamberlain SD, Moorman AR, Jones LA, et al. 2′-Ester prodrugs of the varicella-zoster antiviral agent, 6-methoxypurine arabinoside. Antiviral Chemistry and Chemotherapy 1992;3:371-8.
21. Moorman AR, Chamberlain SD, Jones LA, et al. 5′-Ester prodrugs of the varicella-zoster antiviral agent, 6-methoxypurine arabinoside. Antiviral Chemistry and Chemotherapy 1992;3:141-6.
22. Szczech GM, Tucker WE Jr. Neurotoxic effects of the anti-varicella zoster virus agent 2′-valeryl-6-methoxypurine arabinoside in monkeys and rats dosed orally for 90 days. Fundam Appl Toxicol 1992;18:314-20.
23. Bischofberger N, Hitchcock MJM, Chen MS, et al. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38:2387-91.
24. Lipman JM, Reichert JA, Davidovich A, Anderson TD. Species differences in nucleotide pool levels of 2′, 3′-dideoxycytidine: a possible explanation for species-specific toxicity. Toxicol Appl Pharmacol 1993; 123:137-43.
25. Werth JL, Zhou B, Nutter LM, Thayer SA. 2′,3′-dideoxycytidine alters calcium buffering in cultured dorsal root ganglion neurons. Mol Pharmacol 1994;45:1119-24.